OptimizeRx (NASDAQ:OPRX) Shareholders Have Endured a 83% Loss From Investing in the Stock Three Years Ago
Critical Insights From OptimizeRx Analyst Ratings: What You Need To Know
JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $16 Price Target
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $16
JMP Securities analyst Constantine Davides maintains $OptimizeRx(OPRX.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 23.6%
New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
OptimizeRx | 10-Q: Quarterly report
OptimizeRx Price Target Raised to $16.00/Share From $15.00 by JMP Securities
12 Health Care Stocks Moving In Wednesday's Intraday Session
OptimizeRx Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Expert Ratings For OptimizeRx
OptimizeRx Is Maintained at Buy by Stifel
Stifel Maintains Buy on OptimizeRx, Maintains $13 Price Target
OptimizeRx Analyst Ratings
Stifel Nicolaus Reaffirms Their Buy Rating on OptimizeRx (OPRX)
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), PepGen Inc. (PEPG) and RegenXBio (RGNX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX), Immunocore Holdings (IMCR) and Acadia Healthcare (ACHC)
Earnings Call Summary | OptimizeRx(OPRX.US) Q1 2024 Earnings Conference
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and OptimizeRx (OPRX)
OptimizeRx Corporation (OPRX) Q1 2024 Earnings Call Transcript
OptimizeRx Expects FY24 Rev to Be at Least $100 M With Adj EBITDA of at Least $11 M